C. Massard

D. Planchard, C. Caramella, L. Lacroix, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

A. Geraud, D. Planchard, J. Delahousse, 2020, Cancers.

Photokilling of Escherichia coli Using Hybrid Titania Nanoparticles Suspended in an Aqueous Liquid

E. Caudron, M. Bonnet, C. Massard, 2013 .

Nanoporous surface wetting behavior: the line tension influence.

C. Massard, V. Raspal, K. Awitor, 2012, Langmuir : the ACS journal of surfaces and colloids.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

C. Lindsay, P. Vielh, Y. Loriot, 2016, BMC Cancer.

Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.

D. Planchard, G. Le Teuff, J. Soria, 2014, Lung cancer.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

J. Bono, Y. Loriot, K. Fizazi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.

A. D'Amico, F. Saad, R. V. D. van den Bergh, 2022, European urology.

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.

J. Soria, D. Khayat, F. Goldwasser, 2010, European journal of cancer.

Cutaneous side‐effects in patients on long‐term treatment with epidermal growth factor receptor inhibitors

J. Soria, V. Boige, C. Robert, 2009, The British journal of dermatology.

L’année 2015 à travers le regard du comité de rédaction du Bulletin du cancer

N. Magné, J. Blay, J. Thariat, 2016 .

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.

T. Messai, R. Crevoisier, S. Koscielny, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel and bone-targeted agents for CRPC.

B. Escudier, Y. Loriot, K. Fizazi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome.

J. Patard, K. Kitikidou, Y. Loriot, 2015, Urologic oncology.

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.

J. Soria, L. Lacroix, A. Hollebecque, 2022, European journal of cancer.

Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database.

P. Wust, V. Budach, A. Briganti, 2015, European urology focus.

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials

Cyrus Chargari, J. Soria, A. Levy, 2012, Investigational New Drugs.

Environmental Toxicity and Antimicrobial Efficiency of Titanium Dioxide Nanoparticles in Suspension

M. Bonnet, C. Massard, P. Veisseire, 2015 .

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.

J. Bellmunt, Y. Loriot, K. Fizazi, 2013, Clinical genitourinary cancer.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

X. Paoletti, J. Soria, J. Armand, 2018, British Journal of Cancer.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

N. Girard, J. Soria, E. Lanoy, 2018, European journal of cancer.

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

F. Barlesi, N. Vey, C. Massard, 2022, ESMO open.

Patterns of progression in patients treated for immuno-oncology antibodies combination

J. Soria, J. Armand, E. Castañón, 2020, Cancer Immunology, Immunotherapy.

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies

J. Ajani, J. Soria, E. Deutsch, 2015, Oncology.

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Y. Drew, R. Plummer, J. Soria, 2013, Investigational New Drugs.

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

S. Kaye, T. Yap, D. Olmos, 2011, Clinical Cancer Research.

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

R. Salazar, J. Soria, J. Armand, 2012, Investigational New Drugs.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.

Tumor assessment criteria in phase I trials: beyond RECIST.

J. Soria, S. Koscielny, A. Levy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

O. Mir, J. Soria, E. Castañón, 2018, European journal of cancer.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

C. Robert, B. Besse, O. Lambotte, 2019, The Lancet. Haematology.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

X. Paoletti, J. Soria, V. Ribrag, 2018, Investigational New Drugs.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

T. de Baère, F. André, G. Vassal, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ERCC 1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy

E. Brambilla, F. André, J. Soria, 2011 .

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.

E. Brambilla, F. André, J. Soria, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Therapy for Early Lung Cancer: Reflections and Perspectives

J. Pignon, C. Massard, 2006 .

Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

J. Soria, J. Armand, E. Deutsch, 2008, Nature Clinical Practice Oncology.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Baselga, J. Soria, J. Cortes, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[Standard of care of carcinomas on cancer of unknown primary site in 2016].

P. Hofman, C. Massard, M. Ilié, 2016, Bulletin du cancer.

Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer

K. Fizazi, C. Massard, M. Gross-goupil, 2009 .

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

T. de Baère, M. Ducreux, S. Michiels, 2017, European journal of cancer.

Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial—Interim results.

A. Eggermont, T. Baère, F. André, 2013 .

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

J. Soria, E. Lanoy, A. Hollebecque, 2016, PloS one.

What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.

F. Montorsi, G. Gandaglia, A. Briganti, 2015, Urologic oncology.

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

O. Sartor, J. D. de Bono, C. Massard, 2011, The oncologist.

Wound healing delay after central venous access following DCF/VEGF-trap therapy

J. Soria, Y. Loriot, C. Ferté, 2009, Investigational New Drugs.

Risk factors for brain relapse in patients with metastatic breast cancer.

F. André, A. Dunant, M. Spielmann, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.

S. Nénan, Y. Loriot, K. Fizazi, 2020, Clinical genitourinary cancer.

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

T. Tammela, A. Snapir, K. Fizazi, 2016, European urology.

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2015, European journal of cancer.

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Y. Loriot, K. Fizazi, C. Massard, 2015, Expert review of anticancer therapy.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

M. Gleave, Y. Loriot, K. Fizazi, 2015, European urology.

Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC).

V. Kataja, N. James, Jorge A. Garcia, 2014 .

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

S. Oudard, G. Gravis, K. Fizazi, 2014, European journal of cancer.

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2010, European journal of cancer.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

T. de Baère, F. André, G. Vassal, 2016, European Journal of Cancer.

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

T. Ikonen, G. Curigliano, A. Italiano, 2020, ESMO Open.

Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.

T. Cloughesy, C. Balañà, W. Fiedler, 2019, Journal of Clinical Oncology.

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B‐cell lymphoma: Results of LNH‐EP1 study

J. Soria, L. Lacroix, J. Rossignol, 2021, American journal of hematology.

L. Zitvogel, N. Chaput, J. Adam, 2022, Journal of experimental & clinical cancer research : CR.

Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.

S. Culine, Y. Loriot, K. Fizazi, 2020, European journal of cancer.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

C. Massard, A. Zivi, J. de-Bono, 2010, Clinical genitourinary cancer.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

J. Soria, C. Caramella, B. Besse, 2015, Lung cancer.

An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.

C. Lefebvre, J. Soria, P. Vielh, 2020, European urology oncology.

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.

A. Tolcher, V. Lazar, J. Soria, 2013, European journal of cancer.

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

J. Soria, E. Deutsch, N. Amellal, 2015, British Journal of Cancer.

The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer.

K. Fizazi, C. Massard, A. Chauchereau, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

K. Harrington, E. Copson, K. Rieger-Christ, 2022, JCO clinical cancer informatics.

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

T. Baère, V. Lazar, J. Soria, 2013, Investigational New Drugs.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

T. de Baère, V. Lazar, J. Soria, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Hybrid sol gel coating: A solution to prevent interactions between plasticized poly(vinyl chloride) and injectable drugs?

V. Sautou, L. Bernard, R. Cueff, 2014 .

QT interval prolongation among patients treated with angiogenesis inhibitors

J. Soria, A. Cohen, F. Boccara, 2009, Targeted Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center.

J. Soria, F. Scotté, V. Ribrag, 2021, Journal of Clinical Oncology.

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.

A. Italiano, J. Soria, E. Cohen, 2014, European journal of cancer.

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus

A. Italiano, J. Soria, A. Hollebecque, 2014 .

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

A. Italiano, P. Schőffski, P. Schöffski, 2019, Journal of Clinical Oncology.

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

E. Copson, K. Rieger-Christ, O. Michielin, 2022, Cancers.

302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors

J. Coindre, M. Toulmonde, A. Italiano, 2015 .

Immunosenescence, inflammaging, and cancer immunotherapy efficacy

N. Chaput, B. Besse, S. Champiat, 2022, Expert review of anticancer therapy.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

O. Lambotte, A. Hollebecque, S. Champiat, 2019, JAMA oncology.

Efficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR).

B. Escudier, Y. Loriot, M. Palma, 2013 .

Cytotoxicity Study of Gold Nanoparticles on the Basal-Like Triple-Negative HCC-1937 Breast Cancer Cell Line

C. Massard, O. Awitor, Clémence Dubois, 2018 .

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

G. Le Teuff, B. Escudier, L. Obéric, 2016, European journal of cancer.

[Metronomic chemotherapy in 2011: update and perspectives].

Z. Benbrahim, C. Massard, O. El mesbahi, 2011, Bulletin du cancer.

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

J. Soria, E. Escudier, C. Massard, 2009, Investigational New Drugs.

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial

J. Soria, A. Cohen, S. Ederhy, 2010, Investigational New Drugs.

Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.

C. Robert, S. Ederhy, B. Besse, 2021, European journal of cancer.

Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.

L. Zitvogel, J. Soria, G. Zalcman, 2017 .

Everolimus Versus Axitinib as Second‐line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

B. Escudier, Y. Loriot, K. Fizazi, 2017, Clinical genitourinary cancer.

How to select amongst available options for the treatment of advanced RCC?

B. Escudier, Y. Loriot, K. Fizazi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

S. Culine, D. Pasquier, N. Penel, 2017, Bulletin du Cancer.

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

J. Honnorat, O. Lambotte, F. Bourdain, 2019, Journal of Immunotherapy for Cancer.

How to select targeted therapy in renal cell cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

M. Hidalgo, T. Nayak, K. Stubenrauch, 2017, Clinical Cancer Research.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

J. Soria, J. Armand, V. Ribrag, 2018, European journal of cancer.

Molecular screening for cancer treatment optimization: MOSCATO 01 - A prospective molecular triage trial, interim results

A. Eggermont, T. Baère, F. André, 2013 .

Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.

S. Ammari, S. Champiat, A. Marabelle, 2020, The oncologist.

Inflammatory vocal fold lesions associated with angiogenesis inhibition

J. Soria, J. Bosq, D. Hartl, 2014 .

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

J. Soria, E. Lanoy, C. Robert, 2020, Journal for ImmunoTherapy of Cancer.

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?

J. Soria, S. Postel-Vinay, C. Massard, 2020, European Journal of Cancer.

High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.

L. Schwartz, M. Gönen, Elvire Roblin, 2022, European journal of cancer.

Targeted therapy-induced radiation recall.

J. Soria, C. Robert, E. Deutsch, 2013, European journal of cancer.

Photoactive TiO2 antibacterial coating on surgical external fixation pins for clinical application

S. Descamps, C. Massard, C. Forestier, 2015, International journal of nanomedicine.

Impact of COVID-19 on healthcare organisation and cancer outcomes

D. Planchard, M. Ducreux, S. Michiels, 2021, European Journal of Cancer.

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

S. Culine, B. Escudier, Y. Loriot, 2012, European journal of cancer.

355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients

C. Genestie, A. Paci, C. Balleyguier, 2021, Journal for ImmunoTherapy of Cancer.

Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.

T. de Baère, J. Soria, C. Robert, 2022, European journal of cancer.

Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors

R. Salazar, J. Soria, J. Armand, 2007 .

179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma

R. Plummer, J. Soria, C. Massard, 2008 .

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

L. Collette, D. Lacombe, L. Seymour, 2014, European journal of cancer.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

J. Soria, S. de Botton, V. Ribrag, 2014, Anti-cancer drugs.

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.

J. Soria, E. Lanoy, E. Deutsch, 2016, International journal of cardiology.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

J. Soria, J. Armand, V. Ribrag, 2018, European journal of cancer.

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report

J. Soria, B. Besse, H. Izzedine, 2010, Investigational New Drugs.

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.

W. Hilgers, G. Pignot, J. Walz, 2018, European journal of cancer.

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

B. Escudier, Y. Loriot, K. Fizazi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?

B. Escudier, B. Besse, Y. Loriot, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.

A. Tafreshi, J. Carles, S. Oudard, 2022, European urology.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

J. Droz, A. Kramar, K. Fizazi, 2013 .

Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy.

J. Patard, B. Escudier, Y. Loriot, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

S. Culine, G. Gravis, P. Barthélémy, 2022, European urology.

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.

Y. Loriot, K. Fizazi, C. Vicier, 2019, Clinical genitourinary cancer.

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

S. Oudard, G. Gravis, P. Beuzeboc, 2013 .

Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.

Y. Loriot, K. Fizazi, P. Beuzeboc, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.

O. Lambotte, S. Champiat, A. Marabelle, 2021, European journal of cancer.

Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers.

B. Besse, A. Hollebecque, D. Morel, 2022, Cancer Treatment and Research Communications.

J. Soria, J. Armand, C. Robert, 2016, European journal of cancer.

New agents in metastatic prostate cancer.

K. Fizazi, C. Massard, 2009, European journal of cancer.

Prognostic value of urinary N-telopeptide (uNTx) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases

A. Laplanche, K. Fizazi, C. Massard, 2008 .

Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

F. Penault-Llorca, J. Soria, J. Armand, 2009, Nature Clinical Practice Oncology.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica

C. Sternberg, M. Ducreux, J. Adam, 2018, Tumori.

Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study

F. Scotté, S. Champiat, C. Massard, 2022, Supportive Care in Cancer.

Patient-reported tolerability of adverse events in phase 1 trials

X. Paoletti, J. Soria, E. Lanoy, 2017, ESMO Open.

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

M. Gutiérrez, E. Mouret‐Fourme, P. Chérel, 2011, BMC Cancer.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors

C. Massard, K. Benhadji, S. Pant, 2022, Cancer Chemotherapy and Pharmacology.

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

J. Soria, C. Massard, M. Le Deley, 2012, European journal of cancer.

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour

A. Cesne, J. Soria, J. Armand, 2010, Investigational New Drugs.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

J. Droz, A. Kramar, K. Fizazi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

L. Appleman, G. Gravis, E. Yu, 2022, European urology.

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

ERCC1 inﬂuence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy

E. Brambilla, F. André, R. Pirker, 2011 .

Enzalutamide and sleep apnea: an emerging central nervous system side-effect?

Y. Loriot, C. Massard, G. Roubaud, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Y. Loriot, K. Fizazi, C. Massard, 2015, European urology.

Feasibility of a Chronic Foreign Body Infection Model Studying the Influence of TiO2 Nanotube Layers on Bacterial Contamination

S. Descamps, C. Massard, C. Forestier, 2016 .

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

D. Planchard, B. Besse, L. Mezquita, 2022, Cancers.

Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.

J. Soria, E. Deutsch, A. Levy, 2016, European journal of cancer.

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

D. Planchard, A. Italiano, J. Soria, 2022, JCO precision oncology.

Carcinomas of an unknown primary site: a curable disease?

K. Fizazi, C. Massard, M. Gross-goupil, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Synthesis and characterisation of tantalum-incorporating silica hybrid sol gel thin films for optical applications

J. Mugnier, Wei-ping Zhang, C. Massard, 2006 .

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.

J. Soria, B. Escudier, Y. Loriot, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer

C. Bagnis, C. Massard, L. Campedel, 2022, Cancer medicine.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic

J. Patard, B. Escudier, Y. Loriot, 2018, Clinical and translational radiation oncology.

Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100.

B. Escudier, Y. Loriot, M. Palma, 2012 .

Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.

J. Fütterer, R. V. D. van den Bergh, A. Briganti, 2016, European urology focus.

Bevacizumab-induced laryngeal necrosis.

J. Soria, J. Bosq, D. Hartl, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Salvage High‐Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002‐2012

L. Mariani, P. Pedrazzoli, A. Nagler, 2017, Clinical genitourinary cancer.

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

O. Mir, A. Le Cesne, I. Ray-Coquard, 2022, ESMO open.

7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis

J. Soria, B. Escudier, C. Caramella, 2009 .

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2016 .

Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

L. Appleman, A. Drakaki, E. Yu, 2019, Journal of Clinical Oncology.

Contact line behavior on nanoporous alumina surfaces

Matthew B. Johnson, C. Massard, V. Raspal, 2013 .

Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.

J. Soria, B. Besse, O. Lambotte, 2020, European journal of cancer.

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Y. Loriot, K. Fizazi, C. Massard, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Photopolymerizable hybrid sol gel coating as a barrier against plasticizer release

V. Sautou, L. Bernard, R. Cueff, 2012 .

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

G. Gravis, Y. Loriot, K. Fizazi, 2017, Journal of Immunotherapy for Cancer.

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials

C. Tournigand, O. Mir, J. Soria, 2017, Investigational New Drugs.

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

J. Blay, B. Bui, J. Soria, 2009, European journal of cancer.

Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan‐cancer analysis

T. Heidmann, B. Job, J. Scoazec, 2021, Molecular oncology.

Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research

R. Weichselbaum, X. Paoletti, J. Soria, 2020, Clinical Cancer Research.

[Eruptive nevi associated with sorafenib treatment].

J. Soria, B. Escudier, C. Robert, 2008, Annales de dermatologie et de venereologie.

Otorhinolaryngological Toxicities of New Drugs in Oncology

J. Soria, D. Hartl, N. Saba, 2017, Advances in Therapy.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma.

B. Escudier, Y. Loriot, K. Fizazi, 2016, Clinical genitourinary cancer.

Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice

J. Pignon, J. Soria, J. Trédaniel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Charles Ferté, Laurent Dercle, Samy Ammari, 2016, Clinical Cancer Research.

Emerging circulating biomarkers in glioblastoma: promises and challenges

A. Idbaih, A. Alentorn, L. Lacroix, 2015, Expert review of molecular diagnostics.

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors

K. Shailubhai, M. Reni, J. Soria, 2017, Cancer Chemotherapy and Pharmacology.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors   

G. Kroemer, J. Soria, J. Armand, 2011, Cell cycle.

Hyperprogressive disease: recognizing a novel pattern to improve patient management

J. Soria, B. Besse, C. Ferté, 2018, Nature Reviews Clinical Oncology.

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

R. Margueron, Andrew Lamb, J. Choudhary, 2021, Cancer Research.

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

A. Italiano, W. Tap, J. Merchan, 2021, Investigational New Drugs.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

J. Soria, C. Massard, D. Sarker, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

C. Lefebvre, F. André, M. Lacroix-Triki, 2016, PLoS medicine.

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.

D. Planchard, S. Michiels, F. André, 2020, European journal of cancer.

Late phase 1 studies: concepts and outcomes.

A. Paci, J. Soria, B. Besse, 2021, The Lancet. Oncology.

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

J. Bono, C. Sternberg, M. Borre, 2021, The Lancet.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

B. Mellado, J. Machiels, L. Dirix, 2017, European journal of cancer.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

J. Armand, A. Schernberg, F. Dhermain, 2016, Bulletin du cancer.

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.

C. Sternberg, D. Olmos, S. Bracarda, 2023, Clinical genitourinary cancer.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

A. Font, U. de Giorgi, S. Bracarda, 2018, Clinical Cancer Research.

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study

S. Foulon, P. Vielh, Y. Loriot, 2016, Oncotarget.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

C. Lindsay, P. Vielh, Y. Loriot, 2016, BMC Cancer.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

S. Fröhling, J. Hartman, R. Schlenk, 2020, Nature Medicine.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[Chromosomal rearrangements and fusion genes in carcinoma].

L. Lacroix, C. Massard, N. Auger, 2011, Bulletin du cancer.

Carcinomas of an unknown primary origin—diagnosis and treatment

Christophe Massard, Y. Loriot, K. Fizazi, 2011, Nature Reviews Clinical Oncology.

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

S. Culine, X. Pivot, J. Douillard, 2007, British Journal of Cancer.

Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer

D. Planchard, J. Adam, J. Soria, 2016, Tumori.

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

P. Hegde, T. Powles, J. Sosman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

A. Paci, J. Adam, J. Soria, 2017, European journal of cancer.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab in urothelial cancers

Y. Loriot, C. Massard, P. Lavaud, 2018, Expert review of anticancer therapy.

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

B. Escudier, N. Lassau, J. Michels, 2010, Investigational New Drugs.

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.

Y. Allory, B. Escudier, S. Oudard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

M. Gross, S. Culine, C. Sternberg, 2011, Urology.

Brain Metastases from Breast Cancer: Recursive Partitioning Analysis of Prognostic Factors Including Molecular Subtypes and Treatment

M. Gutiérrez, E. Mouret‐Fourme, C. Massard, 2010 .

Molecular analysis for refractory rare cancers: sequencing battle continues: learnings for the MOSCATO-01 study.

S. Michiels, G. Malouf, A. Hollebecque, 2022, Critical reviews in oncology/hematology.

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Christophe Massard, M. Gross, S. Culine, 2009, Clinical Cancer Research.

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

E. Rasmussen, J. Soria, A. Lockhart, 2019, Cancer Chemotherapy and Pharmacology.

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

David C. Smith, T. Mikkelsen, T. Cloughesy, 2019, Cancer management and research.

Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.

D. Planchard, N. Chaput, F. André, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer

J. Soria, A. Lithio, C. Massard, 2020, Investigational New Drugs.

Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year

A. Ravaud, C. Massard, M. Gross‐Goupil, 2012, Current Urology Reports.

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

A. Cesne, O. Mir, J. Adam, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour stem cell-targeted treatment: elimination or differentiation.

J. Soria, C. Massard, E. Deutsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

Cancer Therapy : Clinical Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

M. Gross, S. Culine, M. Morris, 2009 .

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

T. Tammela, K. Fizazi, C. Massard, 2017, European urology focus.

Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, G. Gravis, P. Beuzeboc, 2014 .

Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).

B. Escudier, Y. Loriot, M. Palma, 2013 .

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

L. Edenbrandt, E. Trägårdh, A. Bjartell, 2016, European urology focus.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

T. Tammela, V. Kataja, N. James, 2014, The Lancet. Oncology.

ODM-201 and the CNS: A clinical perspective.

A. Snapir, T. Sarapohja, K. Fizazi, 2014 .

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

B. Bot, J. Soria, S. Koscielny, 2013, Clinical Cancer Research.

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

D. Planchard, J. Soria, C. Bourgier, 2013, Oncology Research and Treatment.

Vascular disrupting agents: a delicate balance between efficacy and side effects

J. Soria, A. Hollebecque, C. Massard, 2012, Current opinion in oncology.

Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

J. Soria, G. Milano, A. Cohen, 2011, Critical reviews in oncology/hematology.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

T. Tammela, V. Kataja, H. Joensuu, 2017, European urology focus.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Y. Loriot, K. Fizazi, A. Patrikidou, 2013 .

M. Carducci, S. Oudard, Janet E Brown, 2015, European urology.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.

E. Mouret‐Fourme, C. Massard, R. Le Scodan, 2007, International journal of radiation oncology, biology, physics.

Targeting Continued Androgen Receptor Signaling in Prostate Cancer

K. Fizazi, C. Massard, 2011, Clinical Cancer Research.

Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.

B. Escudier, Y. Loriot, K. Fizazi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

J. Bono, M. Wongchenko, A. Font, 2016 .

The postchemotherapy PSA surge syndrome.

R de Crevoisier, A Bossi, B. Escudier, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

J. Adam, J. Soria, M. Chiron, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

J. Soria, J. Armand, E. Castañón, 2017, European journal of cancer.

Interventional Radiology for Local Immunotherapy in Oncology

T. de Baère, J. Soria, C. Robert, 2021, Clinical Cancer Research.

First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

R. Houot, F. Jardin, K. Hoang-Xuan, 2020 .

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.

David C. Smith, T. Mikkelsen, T. Cloughesy, 2016 .

Mise au point du FRancilian Oncogeriatric Group (FROG) pour la prise en charge du cancer de vessie du sujet âgé

S. Culine, C. Durdux, P. Mongiat-artus, 2014 .

[FRancilian Oncogeriatric Group (FROG)'s focus on management of elderly patients with bladder cancer].

S. Culine, C. Durdux, C. Massard, 2014, Bulletin du cancer.

Minimal residual disease in solid neoplasia: New frontier or red-herring?

Y. Castier, J. Soria, P. Mordant, 2012, Cancer treatment reviews.

Antiangiogenic agents and late anastomotic complications

J. Soria, D. Elias, D. Malka, 2010, Journal of surgical oncology.

Implementing precision medicine initiatives in the clinic: a new paradigm in drug development

J. Soria, A. Hollebecque, C. Massard, 2014, Current opinion in oncology.

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

J. Soria, J. Armand, A. Countouriotis, 2010, British Journal of Cancer.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

T. Powles, C. Bascoul-Mollevi, L. Einhorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

A. Italiano, M. Chiron, Chia‐Chi Lin, 2022, Journal for ImmunoTherapy of Cancer.

Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.

M. Ducreux, J. Soria, V. Boige, 2020, European journal of cancer.

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.

D. Planchard, V. Plagnol, J. Adam, 2020, JCO precision oncology.

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

J. Soria, C. Ferté, E. Castañón, 2020, Cancer medicine.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

J. Soria, C. Ferté, J. Merchan, 2019, Investigational new drugs.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2019, European journal of cancer.

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

O. Mir, J. Soria, A. Le Cesne, 2018, European journal of cancer.

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Y. Loriot, K. Olaussen, A. Hollebecque, 2019, Clinical Cancer Research.

Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study

J. Thiery, E. Solary, A. Eggermont, 2019, Experimental and Molecular Therapeutics.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

E. Solary, D. Planchard, A. Eggermont, 2020, npj Precision Oncology.

hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway

G. Kroemer, J. Soria, L. Sabatier, 2006, Oncogene.

Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Castration-resistant , CYP 17 Inhibitor-naïve Prostate Cancer : Results from Extended Follow-up of the ARADES Trial

T. Tammela, V. Kataja, H. Joensuu, 2018 .

Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Chemotherapy-naïve and CYP 17 Inhibitor-naïve Patients : Follow-up from the ARADES and ARAFOR Trials

T. Tammela, K. Fizazi, C. Massard, 2018 .

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

D. Petrylak, Y. Loriot, K. Fizazi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials

J. Blay, O. Mir, A. Le Cesne, 2021, Cancers.

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

C. Le Péchoux, A. Levy, S. Ammari, 2018, European Respiratory Journal.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

W. Mason, J. Machiels, B. Melichar, 2022, ESMO open.

Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment

M. Gutiérrez, E. Mouret‐Fourme, C. Massard, 2011, Journal of Neuro-Oncology.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Donnell, T. Curiel, M. Rebelatto, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of multiparametric magnetic resonance imaging in early detection of prostate cancer

J. Fütterer, R. V. D. van den Bergh, A. Briganti, 2016, Insights into Imaging.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors

J. Soria, D. Ricard, S. Chaturvedi, 2018, Investigational New Drugs.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

S. Peters, J. Soria, A. Stathis, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

J. Bosq, J. Rossignol, V. Ribrag, 2021, Cancer drug resistance.

[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].

J. Blay, M. Wislez, C. Massard, 2010, Bulletin du cancer.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

T. Powles, M. Fishman, S. Srinivas, 2017 .

The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial

T. de Baère, J. Soria, S. Foulon, 2016, Genetics in Medicine.

High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

F. Bertucci, S. Chevret, A. Cesne, 2019, Annals of Oncology.

Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox.

J. Blay, A. Italiano, A. Marabelle, 2022, European journal of cancer.

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

S. Fröhling, J. Lindberg, J. Bergh, 2022, Nature Cancer.

Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network

David Tamborero, Carlos Caldas, Giovanni Apolone, 2021 .

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

Charles Ferté, Mathilde Bateson, Eric Deutsch, 2017, Scientific Reports.

The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.

P. Chanson, X. Mariette, J. Soria, 2020, European journal of cancer.

Intratumoral Immunotherapy: From Trial Design to Clinical Practice

T. de Baère, E. Lanoy, C. Robert, 2020, Clinical Cancer Research.

hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway

G. Kroemer, J. Soria, L. Sabatier, 2013, Oncogene.

Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.

M. Carducci, S. Oudard, Janet E Brown, 2012 .

Online Public Interest in Urological Cancers During the COVID-19 Pandemic: What Can “Dr. Google” Teach Us?

K. Bensalah, A. De la taille, G. Pignot, 2022, European Urology Open Science.

Androgen Receptor Pathway in Prostate Cancer: Old Target and New Drugs

K. Fizazi, C. Massard, 2012 .

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

E. Solary, T. de Baère, S. Michiels, 2018, European journal of cancer.

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.

B. Escudier, F. Massari, Y. Loriot, 2015, European urology.

Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, G. Gravis, K. Fizazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016 .

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

D. Reardon, L. Siu, Juanita Lopez, 2021, Cancer.

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

D. Planchard, C. Caramella, L. Lacroix, 2020 .

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

M. Hidalgo, M. Martínez-García, K. Lechner, 2020, Translational oncology.

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

N. Magné, A. Levy, C. Massard, 2012, Clinical genitourinary cancer.

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA

J. Soria, H. Izzedine, C. Massard, 2010, NDT plus.

Are phase I trials safe for older patients?

O. Mir, J. Soria, E. Castañón, 2017, Journal of geriatric oncology.

Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.

M. Mathieu, F. André, M. Spielmann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors.

J. Patard, B. Escudier, K. Fizazi, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers

J. Castelli, R. de Crevoisier, V. Quillien, 2022, Advances in radiation oncology.

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

C. Sternberg, M. Borre, M. Wongchenko, 2020 .

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Y. Allory, B. Asselain, O. Rouvière, 2017, European urology focus.

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

T. Chevalier, T. le Chevalier, C. Massard, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial

A. Eggermont, T. Baère, F. André, 2015 .

MET receptor amplification drives resistance to Anti-EGFR therapies

J. Soria, L. Lacroix, E. Castañón, 2019, Journal of Immunotherapy and Precision Oncology.

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

U. Banerji, S. Kaye, T. Yap, 2012, PloS one.

An Ecoconceptual Synthesis Process of Silver Nanoparticles Integrating the Valorization of a Food Waste: The Peanut Shell

C. Massard, K. Awitor, 2022, Journal of Biomaterials and Nanobiotechnology.

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

A. Aupérin, V. Ribrag, C. Massard, 2022, Haematologica.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Exploring the optimal use of alectinib.

B. Besse, C. Massard, D. Enrico, 2019, The Lancet. Respiratory medicine.

Case Report: Expanding the tumour spectrum associated with the Birt-Hogg-Dubé cancer susceptibility syndrome

J. Lamoril, E. Longchampt, C. Massard, 2014, F1000Research.

High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.

B. Escudier, Y. Loriot, A. Laplanche, 2015, European journal of cancer.

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

P. López-Casas, D. Olmos, P. Flohr, 2021, Cancers.

One-pot Synthesis of TiO2 Nanoparticles in Suspensions for Quantification of Titanium Debris Release in Biological Liquids

D. Bourdeaux, E. Caudron, T. Devers, 2012 .

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.

B. Escudier, Y. Loriot, A. Laplanche, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

V. Haddad, B. Escudier, J. Lumbroso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PALLIA 10 score in phase I cancer studies

J. Soria, F. Scotté, V. Ribrag, 2022, BMJ supportive & palliative care.

Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

T. Tammela, K. Fizazi, C. Massard, 2015 .

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

T. Tammela, A. Snapir, K. Fizazi, 2014 .

Sequential therapy in renal cell carcinoma

B. Escudier, K. Fizazi, C. Massard, 2009, Cancer.

Boosted Photoactivity of Titania Nanotube Layers Doped with a Suspension of Gold Nanoparticles

C. Massard, S. Pairis, O. Awitor, 2017 .

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

B. Escudier, Y. Loriot, K. Fizazi, 2016, European journal of cancer.

Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.

T. Tammela, V. Kataja, H. Joensuu, 2014 .

862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

K. Fizazi, C. Massard, P. Bono, 2014 .

ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data.

S. Culine, N. James, A. Moilanen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours.

J. Patard, B. Escudier, Y. Loriot, 2014, European journal of cancer.

A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma.

R. de Crevoisier, K. Fizazi, A. Patrikidou, 2013, Urologic oncology.

Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study

D. Planchard, S. Michiels, F. André, 2019, Annals of Oncology.

Impact of COVID-19 Pandemic on Cancer Research

L. Zon, D. Tuveson, A. Ribas, 2020, Cancer Cell.

Who dies from prostate cancer?

B. Escudier, Y. Loriot, M. Palma, 2014, Prostate Cancer and Prostatic Disease.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

J. Soria, R. Sun, L. Dercle, 2017, European journal of cancer.

Multiple immune-related toxicities in cancer patients treated with anti-programmed death 1 immunotherapies: a new surrogate marker for clinical trials?

C. Robert, B. Besse, O. Lambotte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon

F. Carbonnel, C. Massard, J. Michot, 2021, EXCLI journal.

796PEARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS.

B. Escudier, M. Gizzi, Y. Loriot, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.

S. Culine, S. Oudard, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Detection of additional occult malignancy though profiling of ctDNA in late-stage cancer patients.

L. Lacroix, Y. Loriot, A. Hollebecque, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

S. Champiat, C. Massard, C. Baldini, 2019, OncoTargets and therapy.

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

C. Szczylik, B. Escudier, K. Fizazi, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).

J. Nemunaitis, J. Marshall, R. Finn, 2017 .

One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?

Y. Loriot, K. Fizazi, C. Massard, 2014, European urology.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

J. Soria, M. Schlumberger, C. Robert, 2016, European journal of cancer.

First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.

J. Soria, C. Massard, C. Tourneau, 2015 .

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

A. Tafreshi, J. Carles, J. Bono, 2019, Journal of Clinical Oncology.

Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

A. Tafreshi, J. Bono, E. Yu, 2019, Journal of Clinical Oncology.

Toll like receptor 3 expression and efficacy of adjuvant treatment with polyadenylic-polyuridylic acid in patients with axillary node positive breast cancer: Results from two randomized trials.

L. Zitvogel, F. André, J. Sabourin, 2006, Journal of Clinical Oncology.

Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study

M. Gross, S. Culine, C. Sternberg, 2008 .

Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

L. Einhorn, A. Necchi, A. Kramar, 2010 .

Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.

C. Balleyguier, C. Robert, B. Besse, 2021, European journal of cancer.

Arades Trial: A First-in-Man, Open-Label, Phase I/II Safety, Pharmacokinetic, and Proof-of-Concept Study of ODM-201 in Patients (PTS) with Progressive Metastatic Castration-Resistant Prostate Cancer (MCRPC)

S. Culine, N. James, K. Fizazi, 2012 .

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

S. Culine, A. Paci, J. Bay, 2021, Cancer medicine.

Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.

S. Culine, J. Bay, G. Gravis, 2017 .

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

E. Solary, O. Mir, T. de Baère, 2018, European journal of cancer.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

E. Solary, T. de Baère, S. Michiels, 2018, Oncotarget.

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

J. Soria, C. Robert, B. Besse, 2022, Cancer treatment reviews.

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

J. Carles, J. Bono, S. Oudard, 2021, Annals of Oncology.

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

K. Saini, E. de Azambuja, M. Saini, 2020, Oncology and Therapy.

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.

G. Le Teuff, B. Escudier, N. Lassau, 2017, European journal of cancer.

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

D. Planchard, S. Michiels, F. André, 2020, JTO clinical and research reports.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085).

S. Culine, C. Sternberg, G. Wilding, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.

C. Lefebvre, F. André, Yu Fu, 2016, Cancer research.

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

C. Genestie, S. Broutin, C. Balleyguier, 2021 .

Identification of new prognostic factors in phase I patients treated by immunotherapy

J. Soria, J. Armand, V. Ribrag, 2016 .

Tumour growth rates and RECIST criteria in early drug development.

F. Bidault, J. Soria, S. Koscielny, 2011, European Journal of Cancer.

Chemotherapy for poor prognosis non seminomatous germ cell tumors (NSGCT): Should doses be reduced at first cycle to prevent acute respiratory distress syndrome (ARDS) in patients with multiple lung metastases?

S. Culine, K. Fizazi, S. Postel-Vinay, 2007 .

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

T. Powles, M. Ahn, M. Maio, 2018, Clinical Trials.

Natural language processing for patient selection in phase I/II oncology clinical trials

J. Soria, S. Mercier, B. Besse, 2021, medRxiv.

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.

A. Hollebecque, L. Verlingue, C. Massard, 2019, JCO clinical cancer informatics.

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

J. Soria, J. Bidart, E. Borghi, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[Prognostic factors for patients with brain metastases].

C. Massard, G. Noël, R. Le Scodan, 2013, Bulletin du cancer.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

J. Thiery, E. Solary, D. Planchard, 2019, Clinical Cancer Research.

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

S. Michiels, J. Soria, F. Barlesi, 2021, Cancer Cell.

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

L. Zitvogel, B. Escudier, D. Enot, 2017 .

Late Recurrent Testicular Seminoma: Histological Evidence Is Required

M. Gizzi, O. Lambotte, C. Lebacle, 2015, Oncology Research and Treatment.

Who dies from prostate cancer in a Western country? A multicenter analysis.

B. Escudier, K. Fizazi, P. Blanchard, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

S. Fröhling, J. Lindberg, J. Bergh, 2020, Nature Medicine.

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

N. Benson, J. Soria, M. Ocker, 2019, European journal of cancer.

Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft-tissue sarcoma patients.

O. Mir, J. Soria, A. Le Cesne, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

J. Soria, L. Dercle, C. Ferté, 2017, Scientific Reports.

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

J. Soria, H. Staines, A. Hollebecque, 2012 .

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

J. Blay, F. Bertucci, S. Chevret, 2021 .

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples

T. Baère, P. Dessen, V. Lazar, 2014, Investigational New Drugs.

Delivery by shock waves of active principle embedded in gelatin-based capsules.

C. Lafon, D. Cathignol, A. Birer, 2008, Ultrasonics sonochemistry.

Metastatic Germ Cell Tumours

Y. Loriot, K. Fizazi, C. Massard, 2014 .

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

D. Petrylak, Y. Loriot, K. Fizazi, 2017 .

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Baselga, J. Soria, J. Cortes, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)

A. Tolcher, C. Takimoto, J. Soria, 2008 .

From theoretical synergy to clinical supra-additive toxicity.

J. Soria, H. Izzedine, C. Massard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors

B. Besse, R. García-Carbonero, L. Mezquita, 2019 .

Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.

D. Planchard, B. Besse, A. Hollebecque, 2019 .

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

B. Besse, J. Taieb, R. García-Carbonero, 2021, Cancers.

Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.

J. Soria, M. Uttenreuther-Fischer, C. Massard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.

S. Kaye, D. Olmos, C. Massard, 2012, European journal of cancer.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development program (phase I trials) at Institut Gustave Roussy.

J. Soria, C. Caramella, P. Vielh, 2013 .

Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study

J. Bono, Y. Loriot, K. Fizazi, 2012 .

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

J. Blay, F. Bertucci, S. Chevret, 2020 .

Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.

J. Soria, T. Lebret, M. Rouanne, 2013, European journal of cancer.

Cannabis et cancer

B. Besse, J. Spano, L. Karila, 2006 .

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

M. Hidalgo, T. Nayak, J. Albanell, 2014 .

Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor

J. Soria, B. Besse, E. Escudier, 2010, Oncology Research and Treatment.

MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma

D. Planchard, X. Paoletti, J. Soria, 2019, Journal of Thoracic Oncology.

Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).

D. Planchard, X. Paoletti, J. Soria, 2018 .

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

J. Soria, A. Cohen, S. Ederhy, 2012, Investigational New Drugs.

Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013)

Y. Drew, R. Plummer, J. Soria, 2013 .

Management of trophoblastic tumors : review of evidence, current practice, and future directions

C. Massard, P. Bolze, C. Lefeuvre-plesse, 2023, Expert review of anticancer therapy.

Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).

J. Bono, C. Sternberg, M. Wongchenko, 2020 .

Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib

Linda Chami, Nathalie Lassau, Serge Koscielny, 2012, Investigational New Drugs.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

X. Paoletti, J. Soria, J. Armand, 2018, British Journal of Cancer.

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

X. Paoletti, V. Ribrag, A. Hollebecque, 2019 .

10PSafety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

X. Paoletti, V. Ribrag, A. Hollebecque, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?

B. Geoerger, C. Massard, N. Gaspar, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being?

J. Soria, E. Jacquelet, T. Lebret, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US)

V. Lazar, J. Soria, S. Koscielny, 2007 .

Toward a better dialogue between neuro-oncologists and phase I investigators.

J. Soria, U. Banerji, S. Kaye, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Advances in adults' gliomas biology, imaging and treatment].

F. Ducray, A. Idbaih, D. Ricard, 2010, Bulletin du cancer.

[Bone targeted therapies: new agents].

C. Massard, S. Vignot, C. Barth, 2013, Bulletin du Cancer.

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

S. Ou, K. Steele, M. Rebelatto, 2016 .

Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?

J. Soria, C. Bourgier, C. Moldovan, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

J. Blay, F. Bertucci, S. Chevret, 2023, The Lancet. Oncology.

DeepOS: pan-cancer prognosis estimation from RNA-sequencing data

S. Christodoulidis, H. Vanacker, D. Morel, 2021, medRxiv.

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours

A. Italiano, J. Bendell, B. Carneiro, 2020 .

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.

Robin L. Jones, J. Blay, A. Italiano, 2020 .

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

J. Bono, L. Appleman, G. Gravis, 2021 .

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study

F. Barlesi, C. Touzeau, C. Massard, 2023, ESMO open.

[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].

J. Soria, B. Besse, A. Hollebecque, 2012, Bulletin du cancer.

Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.

K. Hoang-Xuan, M. Sanson, A. Idbaih, 2022, European journal of cancer.

Open Peer Review Invited Referee Responses Case Report: Expanding the Tumour Spectrum Associated with the Birt-hogg-dubé Cancer Susceptibility Syndrome [v1; Ref Status

J. Lamoril, E. Longchampt, C. Massard, 2022 .

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

M. Gross, S. Culine, C. Sternberg, 2011, Urology.

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

O. Sartor, J. D. de Bono, C. Massard, 2011, The oncologist.

Targeting Continued Androgen Receptor Signaling in Prostate Cancer

K. Fizazi, C. Massard, 2011, Clinical Cancer Research.

Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

J. Soria, G. Milano, F. Boccara, 2011, Critical reviews in oncology/hematology.

[2015 through the eyes of the Bulletin of Cancer editorial board].

N. Magné, J. Blay, J. Thariat, 2016, Bulletin du cancer.

Annals of Oncology

Horton, R. A. Miller, A. Lister, 1991, Springer US.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

N. Paragios, J. Soria, J. Scoazec, 2018, The Lancet. Oncology.

Vascular disrupting agents: a delicate balance between efficacy and side effects

J. Soria, A. Hollebecque, C. Massard, 2012, Current opinion in oncology.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors].

B. Besse, S. Champiat, A. Marabelle, 2021, Bulletin du cancer.

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

M. Gutiérrez, E. Mouret‐Fourme, P. Chérel, 2011, BMC Cancer.

[Treatment of testicular cancer].

S. Culine, J. Droz, K. Fizazi, 2013, Bulletin du cancer.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.

Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being?

J. Soria, E. Jacquelet, T. Lebret, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

B. Bot, J. Soria, S. Koscielny, 2013, Clinical Cancer Research.

Environmental Toxicity and Antimicrobial Efficiency of Titanium Dioxide Nanoparticles in Suspension

M. Bonnet, C. Massard, P. Veisseire, 2015 .

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

J. Soria, J. Armand, E. Castañón, 2017, European journal of cancer.

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study

A. Hollebecque, C. Massard, C. Quivoron, 2021 .

[The breakthrough of personalized medicine, new hopes and new challenges].

A. Schernberg, R. Flippot, L. Verlingue, 2017, Bulletin du cancer.

Sequential therapy in renal cell carcinoma

B. Escudier, K. Fizazi, C. Massard, 2009, Cancer.

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.

J. Shih, A. Italiano, C. Basson, 2021 .

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

A. Tafreshi, S. Oudard, G. Gravis, 2021, Annals of Oncology.

[Nivolumab, a new hope in non-small cell lung cancer].

B. Besse, R. Flippot, M. Wislez, 2015, Bulletin du cancer.

Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN-COMETE

E. Baudin, M. Haissaguerre, R. Libé, 2023, European Journal of Cancer.

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

J. Adam, J. Soria, M. Chiron, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.